C
Cytovation
Developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition
About Cytovation
Cytovation ASA is a biotechnology company specializing in the development of novel immunotherapies aimed at treating various types of cancer. Leveraging over 15 years of research from the University of Bergen and Haukeland University Hospital, Cytovation focuses on engineering highly stable synthetic peptides with unique antitumoral properties. The company's lead candidate, CyPep-1, is designed to stimulate the immune system to recognize and eradicate tumors through a dual mode of action. Cytovation primarily serves patients with cancer, operating within the oncology market. The business model revolves around the development and commercialization of innovative cancer treatments, generating revenue through partnerships, licensing agreements, and eventual product sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Bergen, Norway
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 45.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Skin Care, Dermatology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2025 | $6M | $100M | Sandwater | ↗ |
| SERIES A✓Equity / VC | Jun 2023 | $8M | $100M | Canica · Sandwater | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Cytovation is 1.4K monthly website visits, down 58.8% over the last three months. Cytovation's team declined 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Canica
Sandwater
Other known investors1 additional known investor
University of Bergen (UiB)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytovation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytovation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.